PTC Therapeutics plans to talk to regulators about regulatory submissions for sepiapterin after the drug met the main goal of a Phase 3 study. The small molecule is a potential treatment for phenylketonuria, a rare enzyme deficiency.
Analysts noted that Evrysdi would be priced significantly lower than Biogen's Spinraza or Novartis' Zolgensma. While this will provide a market advantage, it would also yield lower per-patient revenues.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The company hopes that PTC299's dual mechanism of action can both inhibit replication of the SARS-CoV-2 while alleviating the inflammation associated with severe Covid-19.